Infasurf® (calfactant) is the only natural, FDA-approved surfactant manufactured in the U.S. by a unique calf lung lavage method. This process yields a surfactant that closely mirrors native calf lung surfactant in both composition and activity.
Made to do more.
Mirrors native lung surfactant.
Infasurf® (calfactant) resembles native calf lung surfactant in both composition and activity due to our lung lavage manufacturing process.
- Infasurf has the highest SP-B to phospholipid ratio of any exogenous surfactant1
- Infasurf® (calfactant) has lower dynamic viscosity.2
All essential components of native calf lung surfactant are maintained in Infasurf® (calfactant) due to our unique lavage manufacturing process3
Surfactant protein B (SP-B) is essential for forming the surfactant film that lines the alveoli4,5
Infasurf® (calfactant) is the only surfactant that retains natural cholesterol, which aids the rapid spread of the surfactant film during respiration6
High SP-B to phospholipid ratio
Infasurf has the highest SP-B to phospholipid ratio of any exogenous surfactant1
SP-B plays a critical role in overall surfactant effectiveness.4,5
Disclaimer:
Preclinical and biologic testing do not predict clinical effects.
Table does not imply clinical superiority of Infasurf® (calfactant).
Safety Information:
Infasurf (calfactant) should be administered under the supervision of clinicians experienced in the acute care of newborn infants with respiratory failure who require intubation. Rapid and substantial increases in blood oxygenation and improved lung compliance often follow Infasurf instillation/ Close clinical monitoring and surveillance following administration may be needed to adjust oxygen therapy and ventilator pressures appropriately.
Infasurf® (calfactant) has lower dynamic viscosity.2
Low resistance to flow (dynamic viscosity) may improve the uniformity of distribution in the lung.
Dynamic Viscosities of Lung Surfactants2
Graphic goes here
Infasurf’s unique composition and low viscosity allows for fast distribution to the distal airways2.
At room and body temperature, Infasurf has lower dynamic viscosity than Curosurf®(poractant alfa) and Survanta®(beractant)2.
Dynamic viscosity is only slightly changed by temperature
Approximate Dynamic Viscosities of Common Substances7,8
Infographic goes here (
Disclaimer:
There are no prospective, randomized clinical trials comparing Infasurf® and Curosurf® with respect to safety or efficacy.
References:
1. Notter RH. Lung Surfactants. Michael Dekker, New York, 2000, pp 171-232; 319-345. 2. Swartz D, Klein W, Row S, et al. Comparison of dynamic viscosities of lung surfactant drugs. Poster presented Hot Topics. 2017. 3. Component-specific surface and physiological activity in bovine-derived lung surfactants H Notter a b c, Z Wang a, E.A Egan d e, B.A Holm d f Chemistry and Physics of Lipids Volume 114, Issue 1, January 2002, Pages 21-34 4. Mizuno K, Ikagami M, Chen C-M, et al. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res. 1995;37:271-276. 5. Hall SB, Vemkitaraman AR, Whitsett JA, et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis. 1992;145:24-30. 6. Kim K, Choi S, Zell Z, et al. Effect of cholesterol nanodomains on monolayer morphology and dynamics. Proc Natl Acad Sci USA. 2013;110:E3054-60. 7. Infasurf® (calfactant) Intratracheal Suspension Prescribing Information, ONY Biotech, March 2018. 8. Curosurf® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA, Inc. December 2014. 9. Survanta® (beractant) Intratracheal Suspension Prescribing Information, AbbVie, Inc. December 2012. 10. Retrieved from https://epakmachinery.com/viscosity-chart-1/ 11. Retrieved from https://en.wikipedia.org/wiki/Saline_water
Cost Effective
Chart Here
Infasurf vial sizes enable clinicians to treat 73% of patients with a single vial.
Only 37% of patients can be treated with a single vial of Curosurf.
An independent study found the average cost per patient was 38% less with Infasurf compared to Curosurf.4
another graphic here?
Two vial sizes directly related to dose volumes minimize waste
Disclaimer:
There are no prospective, randomized clinical trials comparing Infasurf and Curosurf with respect to safety or efficacy.
References:
1. Infasurf® (calfactant) Intratracheal Suspension Prescribing Information, ONY Biotech, March 2018. 2. Curosurf® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA Inc. December 2014. 3. Trembath A, Hornik CP, Clark R, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163(4):955-960. 4. Zayek MM, Eyal FG, Smith RC. Comparison of the pharmacoeconomics of calfactant and poractant alfa in surfactant replacement therapy. JPPT. 2018;23(2):146-151.
